Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Exec. VP of WW Sales and Mktg | April 09, 2020 | April 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date April 09, 2020 · Filed April 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,663 |
Ending reported balance
After 2020-04-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-04-09 · Exercise / conversion · Acquired 4,000 · Balance 6,940 F1: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Row 2 · 2020-04-09 · Sale · Disposed 4,000 · Balance 2,940 F1: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F2: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2020-04-10 · Exercise / conversion · Acquired 2,065 · Balance 5,005 F3: Restricted stock units convert into common stock on a one-for-one basis. Row 4 · 2020-04-10 · Tax withholding · Disposed 1,342 · Balance 3,663 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2023-12-31 | Direct | 114,474 |
Reported balance
After 2020-04-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-09 · Exercise / conversion · Disposed 4,000 · Balance 114,474 F1: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5: This option, representing a right to purchase a total of 199,759 shares, was granted on December 31, 2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. 49,939 shares from this award were previously exercised in December 2015. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-04-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-10 · Exercise / conversion · Disposed 2,065 · Balance 0 F3: Restricted stock units convert into common stock on a one-for-one basis. F4: On December 14, 2016, December 4, 2017, and December 7, 2018 the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 14, 2017, December 4, 2018 and December 7, 2019 respectively. The scheduled vestings were accelerated by the registrant, and the restricted stock units became vested as of April 10, 2020. Upon vesting, the reporting person received a number of shares of common stock equal to the number of restricted stock units that vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.
F2: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Restricted stock units convert into common stock on a one-for-one basis.
F4: On December 14, 2016, December 4, 2017, and December 7, 2018 the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 14, 2017, December 4, 2018 and December 7, 2019 respectively. The scheduled vestings were accelerated by the registrant, and the restricted stock units became vested as of April 10, 2020. Upon vesting, the reporting person received a number of shares of common stock equal to the number of restricted stock units that vested.
F5: This option, representing a right to purchase a total of 199,759 shares, was granted on December 31, 2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. 49,939 shares from this award were previously exercised in December 2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2019 Filed Nov 12, 2019 22:18 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,000 | $23.02 | $138,120.00 |
DisclosureSEC source: 0000898432-19-001303 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.00 to $23.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 22:18 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 6,000 | $0.93 | $5,580.00 |
DisclosureSEC source: 0000898432-19-001303 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 22:18 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001303 · form4.xml · derivative · entry 7 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,460 Underlying: Common Stock · 6,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 22:18 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 6,000 | $23.06 | $138,360.00 |
DisclosureSEC source: 0000898432-19-001303 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.81 to $23.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 22:18 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 6,000 | $0.93 | $5,580.00 |
DisclosureSEC source: 0000898432-19-001303 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 23:47 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001298 · form4.xml · derivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,460 Underlying: Common Stock · 4,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 23:47 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,000 | $24.10 | $96,400.00 |
DisclosureSEC source: 0000898432-19-001298 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.85 to $24.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 23:47 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 4,000 | $0.93 | $3,720.00 |
DisclosureSEC source: 0000898432-19-001298 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 23:47 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001298 · form4.xml · derivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,460 Underlying: Common Stock · 3,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 23:47 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,000 | $23.90 | $71,700.00 |
DisclosureSEC source: 0000898432-19-001298 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.75 to $24.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 23:47 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 3,000 | $0.93 | $2,790.00 |
DisclosureSEC source: 0000898432-19-001298 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 22:33 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001293 · form4.xml · derivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,460 Underlying: Common Stock · 4,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 22:33 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,000 | $24.98 | $99,920.00 |
DisclosureSEC source: 0000898432-19-001293 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.81 to $25.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 22:33 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 4,000 | $0.93 | $3,720.00 |
DisclosureSEC source: 0000898432-19-001293 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 31, 2019 Filed Nov 1, 2019 22:33 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001293 · form4.xml · derivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,460 Underlying: Common Stock · 3,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 31, 2019 Filed Nov 1, 2019 22:33 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,000 | $24.89 | $74,670.00 |
DisclosureSEC source: 0000898432-19-001293 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.58 to $25.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 31, 2019 Filed Nov 1, 2019 22:33 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 3,000 | $0.93 | $2,790.00 |
DisclosureSEC source: 0000898432-19-001293 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · derivative · entry 9 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,460 Underlying: Common Stock · 3,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,000 | $24.41 | $73,230.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · nonDerivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $24.00 to $24.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 30, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 3,000 | $0.93 | $2,790.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · nonDerivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · derivative · entry 8 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,460 Underlying: Common Stock · 4,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,000 | $23.91 | $95,640.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.70 to $24.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 4,000 | $0.93 | $3,720.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 28, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · derivative · entry 7 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,460 Underlying: Common Stock · 2,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 28, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 2,000 | $23.80 | $47,600.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.75 to $23.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 28, 2019 Filed Oct 31, 2019 01:41 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 2,000 | $0.93 | $1,860.00 |
DisclosureSEC source: 0000898432-19-001288 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 25, 2019 Filed Oct 25, 2019 20:57 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001284 · form4.xml · derivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,460 Underlying: Common Stock · 4,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 25, 2019 Filed Oct 25, 2019 20:57 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,000 | $23.81 | $95,240.00 |
DisclosureSEC source: 0000898432-19-001284 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.50 to $24.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 25, 2019 Filed Oct 25, 2019 20:57 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 4,000 | $0.93 | $3,720.00 |
DisclosureSEC source: 0000898432-19-001284 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:57 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,400 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001284 · form4.xml · derivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,460 Underlying: Common Stock · 2,400 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:57 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 2,400 | $23.47 | $56,328.00 |
DisclosureSEC source: 0000898432-19-001284 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.30 to $24.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:57 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 2,400 | $0.93 | $2,232.00 |
DisclosureSEC source: 0000898432-19-001284 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,768 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 23, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · derivative · entry 9 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,860 Underlying: Common Stock · 4,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 23, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 4,000 | $23.78 | $95,120.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · nonDerivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.55 to $24.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 23, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 4,000 | $0.93 | $3,720.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · nonDerivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 22, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,200 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · derivative · entry 8 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,860 Underlying: Common Stock · 2,200 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 22, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 2,200 | $23.46 | $51,612.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.40 to $24.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 22, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 2,200 | $0.93 | $2,046.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,568 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 21, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · derivative · entry 7 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,060 Underlying: Common Stock · 2,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 21, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 2,000 | $23.00 | $46,000.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 21, 2019 Filed Oct 23, 2019 22:35 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 2,000 | $0.93 | $1,860.00 |
DisclosureSEC source: 0000898432-19-001282 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 18, 2019 Filed Oct 18, 2019 21:38 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001280 · form4.xml · derivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,060 Underlying: Common Stock · 2,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F2 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 18, 2019 Filed Oct 18, 2019 21:38 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 2,000 | $22.90 | $45,800.00 |
DisclosureSEC source: 0000898432-19-001280 · form4.xml · nonDerivative · entry 4 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 18, 2019 Filed Oct 18, 2019 21:38 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 2,000 | $0.93 | $1,860.00 |
DisclosureSEC source: 0000898432-19-001280 · form4.xml · nonDerivative · entry 3 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 17, 2019 Filed Oct 18, 2019 21:38 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001280 · form4.xml · derivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,060 Underlying: Common Stock · 2,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F2 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 17, 2019 Filed Oct 18, 2019 21:38 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 2,000 | $22.60 | $45,200.00 |
DisclosureSEC source: 0000898432-19-001280 · form4.xml · nonDerivative · entry 2 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 17, 2019 Filed Oct 18, 2019 21:38 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 2,000 | $0.93 | $1,860.00 |
DisclosureSEC source: 0000898432-19-001280 · form4.xml · nonDerivative · entry 1 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 22:25 UTC | IRADIMED CORP IRMD · Entity 4896 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000898432-19-001255 · form4.xml · derivative · entry 9 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,060 Underlying: Common Stock · 3,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F5 · derivative.exercise_date: This option, representing a right to purchase a total of 432,775 shares, was granted on 12/31/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 22:25 UTC | IRADIMED CORP IRMD · Entity 4896 | SaleCommon Stock | 3,000 | $21.92 | $65,760.00 |
DisclosureSEC source: 0000898432-19-001255 · form4.xml · nonDerivative · entry 6 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. F4 · price: This transaction was executed in multiple trades at prices ranging from $21.72 to $22.01. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 22:25 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantCommon Stock | 3,000 | $0.93 | $2,790.00 |
DisclosureSEC source: 0000898432-19-001255 · form4.xml · nonDerivative · entry 5 JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,368 F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.